

1 **ENROLLED**

2 **H. B. 2931**

3
4 (By Delegate Ashley and Westfall)

5 [Passed March 12, 2015; in effect ninety days from passage.]

6
7
8
9
10 AN ACT to amend and reenact §60A-2-204 of the Code of West Virginia, 1931, as amended,
11 relating to adding drugs to the classification of schedule I drugs.

12 *Be it enacted by the Legislature of West Virginia:*

13 That §60A-2-204 of the Code of West Virginia, 1931, as amended, be amended and
14 reenacted to read as follows:

15 **ARTICLE 2. STANDARDS AND SCHEDULES.**

16 **§60A-2-204. Schedule I.**

17 (a) Schedule I shall consist of the drugs and other substances, by whatever official name,
18 common or usual name, chemical name, or brand name designated, listed in this section.

19 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
20 following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers,
21 whenever the existence of such isomers, esters, ethers and salts is possible within the specific
22 chemical designation (for purposes of subdivision (34) of this subsection only, the term isomer

1 includes the optical and geometric isomers):

- 2 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)
3 -4-piperidinyl]-phenylacetamide);
- 4 (2) Acetylmethadol;
- 5 (3) Allylprodine;
- 6 (4) Alphacetylmethadol (except levoalphacetylmethadol also known as
7 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);
- 8 (5) Alphameprodine;
- 9 (6) Alphamethadol;
- 10 (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide;
11 1-(1-methyl-2-phenylethyl)-4-(propanilido) piperidine);
- 12 (8) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-
13 4-piperidinyl]-phenylpropanamide);
- 14 (9) Benzethidine;
- 15 (10) Betacetylmethadol;
- 16 (11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4-
17 piperidinyl]-N-phenylpropanamide);
- 18 (12) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-
19 piperidinyl]-N-phenylpropanamide);
- 20 (13) Betameprodine;
- 21 (14) Betamethadol;
- 22 (15) Betaprodine;

- 1 (16) Clonitazene;
- 2 (17) Dextromoramide;
- 3 (18) Diampromide;
- 4 (19) Diethylthiambutene;
- 5 (20) Difenoxylin;
- 6 (21) Dimenoxadol;
- 7 (22) Dimepheptanol;
- 8 (23) Dimethylthiambutene;
- 9 (24) Dioxaphetyl butyrate;
- 10 (25) Dipipanone;
- 11 (26) Ethylmethylthiambutene;
- 12 (27) Etonitazene;
- 13 (28) Etoxadine;
- 14 (29) Furethidine;
- 15 (30) Hydroxypethidine;
- 16 (31) Ketobemidone;
- 17 (32) Levomoramide;
- 18 (33) Levophenacetylmorphan;
- 19 (34) 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
- 20 (35) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-
- 21 piperidinyl]-N-phenylpropanamide);
- 22 (36) Morpheridine;

- 1 (37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 2 (38) Noracymethadol;
- 3 (39) Norlevorphanol;
- 4 (40) Normethadone;
- 5 (41) Norpipanone;
- 6 (42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidinyl]
- 7 propanamide);
- 8 (43) PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 9 (44) Phenadoxone;
- 10 (45) Phenampromide;
- 11 (46) Phenomorphan;
- 12 (47) Phenoperidine;
- 13 (48) Pir tramide;
- 14 (49) Proheptazine;
- 15 (50) Properidine;
- 16 (51) Propiram;
- 17 (52) Racemoramide;
- 18 (53) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
- 19 (54) Tilidine;
- 20 (55) Trimeperidine.
- 21 (c) *Opium derivatives*. -- Unless specifically excepted or unless listed in another schedule,
- 22 any of the following opium immediate derivatives, its salts, isomers and salts of isomers whenever

1 the existence of such salts, isomers and salts of isomers is possible within the specific chemical

2 designation:

- 3 (1) Acetorphine;
- 4 (2) Acetyldihydrocodeine;
- 5 (3) Benzylmorphine;
- 6 (4) Codeine methylbromide;
- 7 (5) Codeine-N-Oxide;
- 8 (6) Cyprenorphine;
- 9 (7) Desomorphine;
- 10 (8) Dihydromorphine;
- 11 (9) Drotebanol;
- 12 (10) Etorphine (except HCl Salt);
- 13 (11) Heroin;
- 14 (12) Hydromorphanol;
- 15 (13) Methyldesorphine;
- 16 (14) Methyldihydromorphine;
- 17 (15) Morphine methylbromide;
- 18 (16) Morphine methylsulfonate;
- 19 (17) Morphine-N-Oxide;
- 20 (18) Myrophine;
- 21 (19) Nicocodeine;
- 22 (20) Nicomorphine;

1 (21) Normorphine;

2 (22) Pholcodine;

3 (23) Thebacon.

4 (d) *Hallucinogenic substances*. -- Unless specifically excepted or unless listed in another
5 schedule, any material, compound, mixture or preparation, which contains any quantity of the
6 following hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers,
7 whenever the existence of such salts, isomers, and salts of isomers is possible within the specific
8 chemical designation (for purposes of this subsection only, the term “isomer” includes the optical,
9 position and geometric isomers):

10 (1) Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase; alpha-ethyl-1H-
11 indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; and AET;

12 (2) 4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names:
13 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;

14 (3) 4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names:
15 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B, Nexus;

16 (4)(A) N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has
17 the acronym 25B-NBOMe.

18 (B) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe).

19 (C) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)

20 (5) 2,5-dimethoxyamphetamine; some trade or other names:
21 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA;

22 (6) 2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;

- 1 (7) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
- 2 (8) 4-methoxyamphetamine; some trade or other names:
- 3 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; PMA;
- 4 (9) 5-methoxy-3, 4-methylenedioxy-amphetamine;
- 5 (10) 4-methyl-2,5-dimethoxy-amphetamine; some trade and other names: 4-methyl-2,5-
- 6 dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
- 7 (11) 3,4-methylenedioxy amphetamine;
- 8 (12) 3,4-methylenedioxymethamphetamine (MDMA);
- 9 (13) 3,4-methylenedioxy-N-ethylamphetamine (also known as – ethyl-alpha-methyl-3,4
- 10 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
- 11 (14) N-hydroxy-3,4-methylenedioxyamphetamine (also known as – hydroxy-alpha-methyl-
- 12 3,4 (methylenedioxy) phenethylamine, and – hydroxy MDA);
- 13 (15) 3,4,5-trimethoxy amphetamine;
- 14 (15) (16) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 15 (17) Alpha-methyltryptamine (other name: AMT);
- 16 (18) Bufotenine; some trade and other names:
- 17 3-(beta-Dimethylaminoethyl)-5-hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N,
- 18 N-dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine;
- 19 (19) Diethyltryptamine; some trade and other names: N, N-Diethyltryptamine; DET;
- 20 (20) Dimethyltryptamine; some trade or other names: DMT;
- 21 (21) 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 22 (22) Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-

- 1 2-methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
- 2 (23) Lysergic acid diethylamide;
- 3 (24) Marihuana;
- 4 (25) Mescaline;
- 5 (26) Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-
- 6 6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
- 7 (27) Peyote; meaning all parts of the plant presently classified botanically as *Lophophora*
- 8 *williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
- 9 plant, and every compound, manufacture, salts, immediate derivative, mixture or preparation of such
- 10 plant, its seeds or extracts;
- 11 (28) N-ethyl-3-piperidyl benzilate;
- 12 (29) N-methyl-3-piperidyl benzilate;
- 13 (30) Psilocybin;
- 14 (31) Psilocyn;
- 15 (32) Tetrahydrocannabinols; synthetic equivalents of the substances contained in the plant,
- 16 or in the resinous extractives of *Cannabis*, sp. and/or synthetic substances, immediate derivatives and
- 17 their isomers with similar chemical structure and pharmacological activity such as the following:
- 18 delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
- 19 delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
- 20 delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
- 21 (Since nomenclature of these substances is not internationally standardized, compounds of
- 22 these structures, regardless of numerical designation of atomic positions covered.)

- 1 (33) Ethylamine analog of phencyclidine; some trade or other names:
2 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl)
3 ethylamine, cyclohexamine, PCE;
- 4 (34) Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-
5 pyrrolidine, PCPy, PHP;
- 6 (35) Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl)
7 -cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine; TCP, TCP;
- 8 (36) 1[1-(2-thienyl)cyclohexyl]pyrrolidine; some other names: TCPy.
- 9 (37) 4-methylmethcathinone (Mephedrone);
- 10 (38) 3,4-methylenedioxypropylvalerone (MDPV);
- 11 (39) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
- 12 (40) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)
- 13 (41) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
- 14 (42) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)
- 15 (43) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
- 16 (44) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
- 17 (45) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
- 18 (46) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) (47) 2-(2,5-Dimethoxy-
19 4-(n)-propylphenyl)ethanamine (2C-P)
- 20 (48) 3,4-Methylenedioxy-N-methylcathinone (Methylone)
- 21 (49) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7, its optical isomers, salts and
22 salts of isomers

- 1 (50) 5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-
2 (dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT)
- 3 (51) Alpha-methyltryptamine (other name: AMT)
- 4 (52) 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT)
- 5 (53) Synthetic Cannabinoids as follows:
- 6 (A) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol {also known as CP
7 47,497 and homologues};
- 8 (B) rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol {also known as CP
9 47,497-C8 homolog};
- 10 (C) [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,
11 7,10,10a-tetrahydrobenzo[c]chromen-1-ol] {also known as HU-210};
- 12 (D) (dexanabinol);
- 13 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo
14 l[c]chromen-1-ol {also known as HU-211};
- 15 (E) 1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018};
- 16 (F) 1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};
- 17 (G) (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-015};
- 18 (H) (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};
- 19 (I) [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as
20 JWH-200};
- 21 (J) 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as JWH-250};
- 22 (K) 2-((1S,2S,5S)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol

- 1 {also known as CP 55,940};
- 2 (L) (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-
3 122};
- 4 (M) (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-
5 398};
- 6 (N) (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
- 7 (O) 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also known
8 as RCS-8};
- 9 (P) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
- 10 (Q) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
- 11 (R) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
- 12 (54) Synthetic cannabinoids or any material, compound, mixture or preparation which
13 contains any quantity of the following substances, including their analogues, congeners, homologues,
14 isomers, salts and salts of analogues, congeners, homologues and isomers, as follows:
- 15 (A) CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
16 YL)phenol);
- 17 (B) H U - 2 1 0 ,
18 [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
19 10A-tetrahydrobenzo[C] chromen-1-OL)];
- 20 (C) HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-
21 2-YL)-6A,7,10,10atetrahydrobe
22 nzo[C]chromen-1-OL);

1 (D) JWH-018, 1-pentyl-3-(1-naphthoyl)indole;

2 (E) JWH-019, 1-hexyl-3-(1-naphthoyl)indole;

3 (F) JWH-073, 1-butyl-3-(1-naphthoyl)indole;

4 (G) JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;

5 (H) JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]

6 (55) Synthetic cannabinoids including any material, compound, mixture or preparation that

7 is not listed as a controlled substance in Schedule I through V, is not a federal Food and Drug

8 Administration approved drug or used within legitimate and approved medical research and which

9 contains any quantity of the following substances, their salts, isomers, whether optical positional or

10 geometric, analogues, homologues and salts of isomers, analogues and homologues, unless

11 specifically exempted, whenever the existence of these salts, isomers, analogues, homologues and

12 salts of isomers, analogues and homologues if possible within the specific chemical designation:

13 (A) Tetrahydrocannabinols meaning tetrahydrocannabinols which are naturally contained in

14 a plant of the genus cannabis as well as synthetic equivalents of the substances contained in the plant

15 or in the resinous extractives of cannabis or synthetic substances, derivatives and their isomers with

16 analogous chemical structure and or pharmacological activity such as the following:

17 (i) DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.

18 (ii) DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.

19 (iii) DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.

20 (B) Naphthoylindoles or any compound containing a 3-(1-Naphthoyl) indole structure with

21 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole

22 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include

1 the following:

2 (i) JWH 015;

3 (ii) JWH 018;

4 (iii) JWH 019;

5 (iv) JWH 073;

6 (v) JWH 081;

7 (vi) JWH 122;

8 (vii) JWH 200;

9 (viii) JWH 210;

10 (ix) JWH 398;

11 (x) AM 2201;

12 (xi) WIN 55,212.

13 (56) Naphylmethylindoles or any compound containing a 1-hindol-3-yl-(1-naphthyl) methane
14 structure with a substitution at the nitrogen atom of the indole ring whether or not further substituted
15 in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This
16 shall include, but not be limited to, JWH 175 and JWH 184.

17 (57) Naphthoylpyrroles or any compound containing a 3-(1-Naphthoyl) pyrrole structure
18 with substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the
19 pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This
20 shall include, but not be limited to, JWH 147 and JWH 307.

21 (58) Naphthylmethylindenes or any compound containing a Naphthylideneindene structure
22 with substitution at the 3-Position of the indene ring whether or not further substituted in the indene

1 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
2 include, but not be limited to, JWH 176.

3 (59) Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with
4 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
5 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
6 the following:

7 (A) RCS-8, SR-18 OR BTM-8;

8 (B) JWH 250;

9 (C) JWH 203;

10 (D) JWH 251;

11 (E) JWH 302.

12 (60) Cyclohexylphenols or any compound containing a 2-(3- hydroxycyclohexyl) phenol
13 structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the
14 cyclohexyl ring to any extent. This shall include the following:

15 (A) CP 47,497 and its homologues and analogs;

16 (B) Cannabicyclohexanol;

17 (C) CP 55,940.

18 (61) Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with
19 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
20 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
21 the following:

22 (A) AM 694;

- 1 (B) Pravadoline WIN 48,098;
- 2 (C) RCS 4;
- 3 (D) AM 679.
- 4 (62) [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-
5 YL]-1-naphthalenymethanone. This shall include WIN 55,212-2.
- 6 (63) Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol
7 structure with substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051 and
8 JWH 133.
- 9 (64) Adamantoylindoles or any compound containing a 3-(-1- Adamantoyl) indole structure
10 with substitution at the nitrogen atom of the indole ring whether or not further substituted in the
11 adamantoyl ring system to any extent. This shall include AM1248.
- 12 (65) Tetramethylcyclopropylindoles or any compound containing A
13 3-tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring
14 whether or not further substituted in the indole ring to any extent and whether or not substituted in
15 the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11.
- 16 (66) N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.
- 17 (67) Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist
18 as demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV and
19 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
20 medical research. Since nomenclature of these substances is not internationally standardized, any
21 immediate precursor or immediate derivative of these substances shall be covered.
- 22 (68) Tryptamines:

- 1 (A) 5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT)
2 (B) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT)
3 (C) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT)
4 (D) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
5 (E) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT)
6 (F) 5-methoxy- α -methyltryptamine (5-MeO-AMT)
7 (G) 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT)
8 (H) 4-hydroxy Diethyltryptamine (4-HO-DET)
9 (I) 5- methoxy- N,N- diallyltryptamine (5-MeO-DALT)
10 (J) 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT)
11 (K) 4-hydroxy Diethyltryptamine (4-HO-DET)

12 (e) *Depressants*. -- Unless specifically excepted or unless listed in another schedule, any
13 material, compound, mixture, or preparation which contains any quantity of the following substances
14 having a depressant effect on the central nervous system, including its salts, isomers and salts of
15 isomers whenever the existence of such salts, isomers and salts of isomers is possible within the
16 specific chemical designation:

- 17 (1) Mecloqualone;
18 (2) Methaqualone.

19 (f) *Stimulants*. -- Unless specifically excepted or unless listed in another schedule, any
20 material, compound, mixture, or preparation which contains any quantity of the following substances
21 having a stimulant effect on the central nervous system, including its salts, isomers and salts of
22 isomers:

- 1 (1) Aminorex; some other names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or
2 4,5-dihydro-5-phenyl-2-oxazolamine;
- 3 (2) Cathinone; some trade or other names: 2-amino-1-phenyl-1- propanone,
4 alpha-aminopropiophenone, 2-aminopropiophenone and norephedrone;
- 5 (3) Fenethylamine;
- 6 (4) Methcathinone, its immediate precursors and immediate derivatives, its salts, optical
7 isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-
8 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1- one;
9 alpha---methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypropylvalerone and/or
10 mephedrone; 3,4-methylenedioxypropylvalerone (MPVD); ephedrone; N-methylcathinone;
11 methylcathinone; AL-464; AL-422; AL- 463 and UR1432;
- 12 (5) (+-) cis-4-methylaminorex; ((+)-cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);
- 13 (6) N-ethylamphetamine;
- 14 (7) N,N-dimethylamphetamine; also known as N,N-alpha- trimethyl-benzeneethanamine;
15 N,N-alpha-trimethylphenethylamine.
- 16 (8) Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and
17 salts of isomers.
- 18 (9) Substituted amphetamines:
- 19 (A) 2-Fluoroamphetamine
- 20 (B) 3-Fluoroamphetamine
- 21 (C) 4-Fluoroamphetamine
- 22 (D) 2-chloroamphetamine

1 (E) 3-chloroamphetamine

2 (F) 4-chloroamphetamine

3 (G) 2-Fluoromethamphetamine

4 (H) 3-Fluoromethamphetamine

5 (I) 4-Fluoromethamphetamine

6 (J) 4-chloromethamphetamine

7 (g) Temporary listing of substances subject to emergency scheduling. Any material,
8 compound, mixture or preparation which contains any quantity of the following substances:

9 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers,
10 salts, and salts of isomers.

11 (2)N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
12 isomers, salts and salts of isomers.

13 (3) N-benzylpiperazine, also known as BZP.

14 (h) The following controlled substances are included in Schedule I:

15 (1) Synthetic Cathinones or any compound, except bupropion or compounds listed under a
16 different schedule, or compounds used within legitimate and approved medical research, structurally
17 derived from 2- Aminopropan-1-one by substitution at the 1-position with Monocyclic or fused
18 polycyclic ring systems, whether or not the compound is further modified in any of the following
19 ways:

20 (A) By substitution in the ring system to any extent with Alkyl, alkylendioxy, alkoxy,
21 haloalkyl, hydroxyl or halide Substituents whether or not further substituted in the ring system by
22 one or more other univalent substituents.

1 (B) By substitution at the 3-position with an acyclic alkyl substituent.

2 (C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or
3 methoxybenzyl groups.

4 (D) By inclusion of the 2-amino nitrogen atom in a cyclic structure.

5 (2) Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as
6 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV and
7 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
8 medical research.